Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Retrospective analysis of lenalidomide and thalidomide in myelofibrosis

Andrew Kuykendall • 25 Aug 2020
Myelofibrosis Myeloproliferative Neoplasms Lenalidomide Thalidomide

Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, explores results from a retrospective analysis of the clinical use and benefit of lenalidomide and thalidomide in myelofibrosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Andrew Kuykendall

1:44
Predicting thrombocytopenia as a result of ruxolitinib treatment in MF
Andrew Kuykendall • 27 Nov 2023
2:06
Thromboembolic event rates in patients with PV: a real-world analysis
Andrew Kuykendall • 27 Nov 2023
2:03
Preliminary results of a Phase II study of fedratinib in patients with MDS/MPN and CNL
Andrew Kuykendall • 27 Nov 2023
1:40
Challenges and options for patients with hydroxyurea-resistant PV
Andrew Kuykendall • 27 Nov 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals